Want to see PTN full AI Analyst Report?
PTN Stock Chart & Stats
$16.05
--
Market closed
$16.05
--
Day’s Range― - ―
52-Week Range$5.61 - $31.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.99K
Market Cap
$18.70M
Enterprise Value$58.27
Total Cash (Recent Filing)$10.16M
Total Debt (Recent Filing)$286.66K
Price to Earnings (P/E)―
Beta-0.25
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.66
Shares Outstanding1,779,275
10 Day Avg. Volume2,746
30 Day Avg. Volume2,993
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.31
Revenue Forecast (FY)$12.50M
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt reduces interest burden and financial distress risk, giving management flexibility to prioritize R&D and partnership deals. Over a 2–6 month horizon this durable balance-sheet strength supports continued program advancement and lowers the probability that near-term cash needs force unfavorable financing.
Non-dilutive Partnership FundingMaterial upfronts and sublicensing inflows validate assets and provide runway without issuing equity. Such partnership-driven cash is a durable structural advantage, enabling IND-enabling work and clinical timelines while preserving shareholder equity, and it also creates contingent future milestones and potential royalties.
High Gross Margins & Partnered Commercial ModelVery high gross margin when revenue is present indicates product economics are scalable and profitable at the gross level. Partnered commercialization (Vyleesi marketed by a third party) lets Palatin capture royalties/milestones while avoiding direct commercial infrastructure costs, a sustainable model for a small biotech advancing multiple programs.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow creates ongoing dependence on external funding or partnership milestones. This structural cash deficit constrains strategic optionality, increases dilution or licensing pressure over time, and makes multi-year clinical development plans contingent on successful financings or deal timing.
Limited Cash Runway / Funding DependenceA runway that extends only to mid-2027 means near-term milestone realization or financing is essential. This dependency makes program timelines vulnerable to receivable delays or higher expenses, raising execution risk: trials could be slowed, partnering terms weakened, or non-dilutive inflows required to avoid equity issuance.
Competitive & Clinical Timing RiskBeing years behind an approved rival reduces addressable market and pricing leverage for later entrants. Combined with unresolved clinical translational risks (e.g., hyperpigmentation uncertainty), timing delays and second-to-market status can materially limit commercial upside and increase the need for differentiated safety/efficacy data to gain market share.
Palatin Technologies News
PTN FAQ
What was Palatin Technologies’s price range in the past 12 months?
Palatin Technologies lowest stock price was $5.61 and its highest was $31.00 in the past 12 months.
What is Palatin Technologies’s market cap?
Palatin Technologies’s market cap is $18.70M.
When is Palatin Technologies’s upcoming earnings report date?
Palatin Technologies’s upcoming earnings report date is Nov 16, 2026 which is in 87 days.
How were Palatin Technologies’s earnings last quarter?
Palatin Technologies released its earnings results on May 13, 2026. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$1.243 by $0.873.
Is Palatin Technologies overvalued?
According to Wall Street analysts Palatin Technologies’s price is currently Overvalued.
Does Palatin Technologies pay dividends?
Palatin Technologies does not currently pay dividends.
What is Palatin Technologies’s EPS estimate?
Palatin Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Palatin Technologies have?
Palatin Technologies has 1,779,275 shares outstanding.
What happened to Palatin Technologies’s price movement after its last earnings report?
Palatin Technologies reported an EPS of -$0.37 in its last earnings report, beating expectations of -$1.243. Following the earnings report the stock price went down -16.011%.
Which hedge fund is a major shareholder of Palatin Technologies?
Currently, no hedge funds are holding shares in PTN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Palatin Technologies
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
PTN Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced: The call highlighted meaningful near-term commercial validation via upfront collaboration revenue, materially reduced net loss, reduced operating cash burn, strong partnership-driven non-dilutive funding and clear progress across peptide and oral MC4R programs (including IP development). Offsetting these positives are increased operating costs, a limited cash runway to mid-2027 that creates funding risk, a deprioritized earlier oral candidate and timing/competitive risks (notably Rhythm's approved product). Clinical risk around hyperpigmentation and the need for further IND/clinic-readout milestones keep the outlook cautious.View all PTN earnings summariesTechnical Analysis
Ownership Overview
11.21% Insiders
1.96% Mutual Funds
22.80% Other Institutional Investors
62.66% Public Companies and
Individual Investors